BMO downgrades Verve Therapeutics saying Lilly buyout deal caps upside

BMO Capital Markets downgraded Verve Therapeutics (VERV) to Market Perform with a $13.50 price target, citing Eli Lilly's (LLY) definitive agreement to acquire the gene-editing specialist. The deal is structured at $10.50 per share cash upfront, plus a contingent value right (CVR) of up to $3 per share tied to a future Phase III trial, valuing the transaction at up to $1.3 billion. The downgrade reflects limited near-term upside for VERV, which is already trading above Lilly's cash offer, as the acquisition is expected to close smoothly by Q3 2025, effectively capping the stock's appreciation potential despite BMO's 70% probability assessment for the CVR payout.

Analysis

BMO Capital Markets has downgraded Verve Therapeutics (VERV) to Market Perform, a direct consequence of the definitive acquisition agreement by Eli Lilly (LLY). The deal structure, consisting of $10.50 in cash per share and a contingent value right (CVR) of up to $3, sets a total potential valuation of $13.50 per share, or approximately $1.3 billion. This transaction effectively caps the near-term appreciation potential for VERV's stock, which has already more than doubled since the announcement and trades at $11.25, above the guaranteed cash offer. The current market price implies that investors are already pricing in a significant portion of the CVR payout. BMO assesses a 70% probability for this CVR payment, but it is contingent on a Phase III trial for Verve's PCSK9 therapy, which is not projected to commence until 2028. With expectations of a smooth deal closure by Q3 2025, underscored by an imminent antitrust review deadline, the investment thesis for Verve has shifted from a fundamental biotech growth story to an M&A arbitrage play where the primary variable is the probability-weighted value and timing of the CVR.

Key Decisions for Investors

• Investors should recognize that Verve's stock is now primarily an M&A arbitrage play, with potential upside capped at the $13.50 total deal value from Eli Lilly, limiting further significant appreciation.
• Any return above the current trading price is entirely dependent on the $3 per share CVR, which carries clinical development risk and a long time horizon, as the payout is tied to a Phase III trial projected to start around 2028.
• Given the high probability of the deal closing by Q3 2025, the primary risk for current shareholders is not deal failure, but rather the risk that the CVR does not pay out in full or at all.